Enliven Therapeutics (NASDAQ:ELVN) Upgraded to Hold at Zacks Research

Enliven Therapeutics (NASDAQ:ELVN) was upgraded by analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a report released on Wednesday, Zacks reports.

Other equities analysts have also issued reports about the stock. HC Wainwright raised their price objective on shares of Enliven Therapeutics from $65.00 to $73.00 and gave the company a “buy” rating in a research report on Monday, October 19th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Thursday, October 15th. Wall Street Zen raised shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 7th. Stifel Nicolaus increased their target price on shares of Enliven Therapeutics from $80.00 to $82.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Finally, The Goldman Sachs Group raised their price target on shares of Enliven Therapeutics from $67.00 to $80.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Ten investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $75.44.

Enliven Therapeutics Price Performance

Shares of ELVN opened at $48.31 on Wednesday. The stock’s 50-day simple moving average is $46.65 and its 200 day simple moving average is $43.56. Enliven Therapeutics has a 52-week low of $14.78 and a 52-week high of $62.32.

Enliven Therapeutics (NASDAQ:ELVN) last issued its earnings results on Thursday, November 5th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.09. Sell-side analysts anticipate that Enliven Therapeutics will post -1.70 earnings per share for the current year.

Insider Activity at Enliven Therapeutics

In other Enliven Therapeutics news, Director J. Scott Garland sold 13,000 shares of the company’s stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $46.67, for a total value of $606,710.00. Following the completion of the sale, the director owned 13,000 shares of the company’s stock, valued at $606,710. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Benjamin Hohl sold 6,018 shares of the stock in a transaction that occurred on Monday, October 19th. The shares were sold at an average price of $38.48, for a total transaction of $231,572.64. Following the transaction, the chief financial officer owned 38,000 shares in the company, valued at $1,462,240. The trade was a 13.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 31,054 shares of company stock valued at $1,493,823. 3.00% of the stock is owned by insiders.

Institutional Investors Weigh In On Enliven Therapeutics

A number of institutional investors have recently made changes to their positions in the business. BlackRock Inc. purchased a new position in Enliven Therapeutics in the 2nd quarter worth $221,255,000. First Light Asset Management LLC lifted its stake in Enliven Therapeutics by 574.1% in the second quarter. First Light Asset Management LLC now owns 1,360,750 shares of the company’s stock worth $69,058,000 after purchasing an additional 1,158,883 shares during the last quarter. Pictet Asset Management Holding SA boosted its position in Enliven Therapeutics by 14.1% during the third quarter. Pictet Asset Management Holding SA now owns 1,325,740 shares of the company’s stock valued at $60,772,000 after buying an additional 163,956 shares during the period. Assenagon Asset Management S.A. boosted its position in Enliven Therapeutics by 276.4% during the third quarter. Assenagon Asset Management S.A. now owns 1,153,973 shares of the company’s stock valued at $52,898,000 after buying an additional 847,399 shares during the period. Finally, Rock Springs Capital Management LP boosted its position in Enliven Therapeutics by 3.5% during the first quarter. Rock Springs Capital Management LP now owns 826,500 shares of the company’s stock valued at $32,399,000 after buying an additional 28,095 shares during the period. Hedge funds and other institutional investors own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule medicines for cancer. Its research centers on precision oncology, with drug candidates designed to target specific proteins involved in tumor growth. The company’s pipeline has included ELVN-001, an investigational BCR-ABL1 inhibitor being studied for chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor developed for cancers driven by HER2. Enliven is based in Boulder, Colorado.